Ganesh Venkataraman Kaundinya
Chief Executive Officer at GlycoEra AG
Profile
Ganesh Venkataraman Kaundinya is the founder.
He founded Momenta Pharmaceuticals, Inc. in 2001, where he held the title of Chief Operating Officer & Chief Scientific Officer from 2017 to 2018.
He is currently the President, Chief Executive Officer & Director at GlycoEra AG since 2022.
In his former positions, Dr. Kaundinya served as the Bioinformatics Director at Consortium for Functional Glycomics from 2000 to 2003 and as a Member-Research Faculty at Harvard University from 1995 to 2000.
He obtained his graduate and doctorate degrees from Massachusetts Institute of Technology.
Ganesh Venkataraman Kaundinya active positions
| Companies | Position | Start |
|---|---|---|
GlycoEra AG
 GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Chief Executive Officer | 2022-05-02 |
Former positions of Ganesh Venkataraman Kaundinya
| Companies | Position | End |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Founder | 2018-10-04 |
Consortium for Functional Glycomics
 Consortium for Functional Glycomics Internet Software/ServicesTechnology Services Consortium for Functional Glycomics provides a networking forum and glycomics resources which enable investigators to reveal functions of glycans and glycan-binding proteins. It offers glycan microarray screening services, a reagent bank, and free access to its extensive data repositories and molecule databases. The company was founded in 2001 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 2002-12-31 |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2000-06-30 |
Training of Ganesh Venkataraman Kaundinya
| Massachusetts Institute of Technology | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Consortium for Functional Glycomics
Consortium for Functional Glycomics Internet Software/ServicesTechnology Services Consortium for Functional Glycomics provides a networking forum and glycomics resources which enable investigators to reveal functions of glycans and glycan-binding proteins. It offers glycan microarray screening services, a reagent bank, and free access to its extensive data repositories and molecule databases. The company was founded in 2001 and is headquartered in La Jolla, CA. | Technology Services |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Ganesh Venkataraman Kaundinya
